NCT02294396 - Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. | Biotech Hunter

Enrollment

649

Participants

Timeline

Start Date

October 28, 2014

Primary Completion Date

September 7, 2016

Study Completion Date

September 7, 2016

Conditions

Overactive Bladder (OAB)

Interventions

DRUG

Mirabegron tablet

orally administered at a dose of 1 tablet once daily after breakfast

DRUG

Solifenacin tablet

orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)

DRUG

Propiverine tablet

orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)

DRUG

Imidafenacin tablet

orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)

DRUG

Tolterodine capsule

orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)

Trial Locations (7)

Unknown

Chugoku

Chūbu

Hokkaido

Kansai

Kantou

Kyushu

Tōhoku